Obesity pillars

Patients' views on the benefits of retatrutide for obesity treatment in a phase 2 trial

Updated

Abstract

Of the 36 participants treated with retatrutide, 76.7% reported achieving their weight reduction goals.

  • Thirty-one of 36 retatrutide-treated participants noted changes in eating behaviors within the first 8 weeks, including reduced frequency and portion sizes.
  • Participants reported feeling less hungry, more satisfied after meals, and experiencing shifts in food preferences.
  • A majority expressed enhanced self-esteem and happiness, with 32 participants feeling good about themselves and 25 feeling happy.
  • Improvements were observed in physical mobility, energy levels, and engagement in social and leisure activities.
  • Some participants reported challenges, including reduced social participation due to adverse events or new eating habits, and frustration related to weight loss expectations.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

I.A.G., C.K., A.H., L.M.N., and K.S.B. are employees and shareholders of Eli Lilly and Company, which funded this study. C.J.M. was an employee of Evidera when this study was conducted and is currently an employee of Kielo Research (UK). H.K. and M.K. are current employees of Evidera-PPD, which was paid by Eli Lilly and Company to conduct this study.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free